Cannabis extract can help treat psychosis
A cannabis extract could help in curing psychosis, according to a study conducted by researchers in the UK. King's College, located in London, found that cannabidiol, a major component of the marijuana plant, does not get its consumers "high", as opposed to THC (tetrahydrocannabinol).
THC can cause a threat to certain psychotic disorders, such as schizophrenia. Experts have warned "skunk" strains can cause higher levels of psychosis, with acute hallucinations, that can cause distress and harm others.
Experts discovered that a single dose of CBD could reduce abnormal brain activity, that triggers these symptoms. CBD is non-psychoactive as compared to other forms that are legally sold.
CBD Oil, high in THC, has been found as a remedy to rare childhood epilepsy in the United States. Due to its medicinal properties, it has been found appropriate to be prescribed to patients.
An experiment was conducted by researchers to test the effectiveness of CBD on patients with psychosis. To test how CBD may counteract these effects the researchers recruited 33 young people flagged by early intervention services as having symptoms of psychos, but who had yet to be diagnosed or treated. Alongside 19 healthy participants their brain activity was scanned and their verbal and memory skills were tested before the half was given CBD and the other half received a placebo. The findings, published in the Journal of the American Medical Association: Psychiatry, showed that brain activity was abnormal for all the patients with psychosis prior to treatment.
Results declared that those treated with CBD had reduced abnormal activity, falling between placebo and healthy group, with improvement in test performance.
With the help of these results, another clinical trial is being launched across hospitals to confirm whether CBD can be used as an alternative to antipsychotic medication.
“If successful, this trial will provide definitive proof of cannabidiol’s role as an antipsychotic treatment and pave the way for use in the clinic,” Dr. Bhattacharyya said. “Our results have started unraveling the brain mechanisms of a new drug that works in a completely different way to traditional antipsychotics.”